🎈 Up Big Today: Find today's biggest gainers (some over 50%!) with our free screenerTry Stock Screener

Citi maintains buy rating on Emerson stock, price target set at $128

EditorIsmeta Mujdragic
Published 11/05/2024, 12:54 PM
EMR
-

On Tuesday, Citi reaffirmed its Buy rating on Emerson (NYSE:EMR) with a consistent price target of $128.00. The firm's analysis followed Emerson's disclosure of their fourth fiscal quarter of 2024 results and the initial outlook for fiscal year 2025.

Emerson's performance was deemed solid by the analyst, with a positive growth outlook and strong operating leverage anticipated to continue. Although the 2% increase in underlying orders for the fourth fiscal quarter, compared to 3% in the third, was seen as slightly underwhelming, it aligned with Emerson's expectations for the second half and full year to be at a low single-digit percentage increase.

In addition to financial results, Emerson announced strategic moves aimed at finalizing its portfolio transformation. These include a proposal to purchase the remaining shares of Aspen Technology (NASDAQ:AZPN) at $240 per share, a figure slightly above the November 4, 2024, closing price of $237.59. This acquisition is estimated to cost around $6.5 billion.

Emerson is also contemplating various options for its Safety & Productivity business, including a potential cash sale.

Furthermore, Emerson has disclosed plans to repurchase approximately $2.0 billion of its stock during fiscal year 2025, with about $1.0 billion expected to be completed in the first fiscal quarter. The proposed acquisition of Aspen Technology is projected to have a neutral effect on Emerson's earnings per share for the fiscal year 2025, even after accounting for the expected synergies from the transaction.

In other recent news, Emerson Electric Co. reported better-than-expected fourth fiscal quarter results and fiscal year 2025 guidance, with earnings per share (EPS) and organic growth surpassing estimates. The company's quarterly net sales increased by 13% to $4.619 billion, and EPS for the quarter was $1.48.

However, Morgan Stanley (NYSE:MS) maintained an Underweight rating on Emerson, citing challenges in the company's guidance and potential negative impacts of strategic moves. Stephens downgraded Emerson shares from Overweight to Equal Weight due to the potential impacts of the Aspen Technology acquisition, while Oppenheimer raised its price target for Emerson shares to $125, reaffirming an Outperform rating on the company.

In other developments, Emerson finalized the sale of its 40% stake in Copeland to Blackstone (NYSE:BX) and made a strategic investment in Symmera. KeyBanc maintained its Overweight rating on Emerson with a price target of $125.

These are the latest developments in Emerson's business strategy and financial performance.

InvestingPro Insights

Emerson's recent strategic moves and financial performance align with several key insights from InvestingPro. The company's solid growth outlook and strong operating leverage, as noted by Citi, are reflected in InvestingPro's data showing a revenue growth of 13.34% over the last twelve months and an impressive gross profit margin of 51.62%.

InvestingPro Tips highlight Emerson's status as a prominent player in the Electrical Equipment industry, which is consistent with its ambitious portfolio transformation plans, including the proposed acquisition of Aspen Technology. The company's commitment to shareholder value is evident in its dividend history, with InvestingPro noting that Emerson has raised its dividend for 53 consecutive years and maintained payments for 54 years.

While Emerson's strategic initiatives are promising, investors should be aware that the stock is trading at a high earnings multiple, according to InvestingPro Tips. This valuation could be influenced by the market's positive reception of the company's growth strategies and consistent dividend performance.

For those interested in a deeper analysis, InvestingPro offers 6 additional tips that could provide further insights into Emerson's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.